Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences
October 15 2024 - 6:00AM
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based
biotechnology company pioneering cell and gene therapies for aging
and age-related diseases, today announced the appointment of Peter
Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief
Operating Officer (COO).
Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho
Neurosciences, welcomed Moriarty to the leadership team: “We are
thrilled to have Peter join Klotho Neurosciences as COO. His
extensive experience across the pharmaceutical industry, both in
the U.S. and globally, will be instrumental as we move forward.
Peter has a remarkable track record, including leadership roles at
multinational pharmaceutical companies in the US and
internationally and an entrepreneurial career highlighted by his
co-founding of Shire Pharmaceuticals. He brings a wealth of
expertise in operational management, strategic execution, and
cultivating corporate culture—assets that will be critical as we
advance our pipeline of innovative therapies.”
Peter Moriarty expressed enthusiasm for his new role: “I am
excited to now be part of the team at Klotho Neurosciences, a
company I became familiar with during my time as a consultant. What
attracted me was its robust portfolio and the significant promise
of its cell and gene therapy platform. I believe Klotho
Neurosciences is uniquely positioned to develop breakthrough
treatments for neurodegenerative diseases like ALS, Alzheimer’s,
and Parkinson’s. With the exclusive worldwide license from the
Autonomous University of Barcelona, backed by patents across the
U.S., Europe, and China, the company is set to revolutionize
treatments based on the secreted form of the Klotho gene (s-KL).
This could be a true game changer in treating neurodegenerative and
age-related disorders, and I’m eager to contribute to this
groundbreaking work.”
Klotho Neurosciences is committed to harnessing the potential of
gene-based therapies to target the root causes of neurodegenerative
diseases and age-related disorders. With Moriarty’s pharmaceutical
experience and leadership skills, the company is poised to
accelerate the development of its therapeutic candidates.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a
biopharmaceutical company pioneering the development of innovative,
disease-modifying cell and gene therapies using a patented secreted
form of the anti-aging Klotho gene (s-KL) to transform the
treatment of neurodegenerative and age-related disorders such as
ALS, Alzheimer's, and Parkinson's disease. The company’s current
portfolio consists of its proprietary cell and gene therapy
programs using DNA and RNA as therapeutics and diagnostics. Other
assets include clinical-stage programs involving antibody biologics
targeting cancer and autoimmune diseases, and drug delivery via a
needle-free dry powder jet autoinjector called Nanoject. The
company is managed by a team of individuals and advisors who are
highly experienced in biopharmaceutical product development and
commercialization.
For more information, contact:
Eric Boyd
Investor Relations
Email: IR@klothoneuro.com
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, such as the Company’s inability to implement its business
plans, identify and realize additional opportunities, or meet or
exceed its financial projections and changes in the regulatory or
competitive environment in which the Company operates. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the documents filed or to be filed by
the Company with the U.S. Securities and Exchange Commission (the
“SEC”) from time to time, which could cause actual events and
results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided herein
is as of the date of this press release, and the Company undertakes
no obligation to update any forward-looking statement, except as
required under applicable law.
Klotho Neurosciences (NASDAQ:KLTO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Klotho Neurosciences (NASDAQ:KLTO)
Historical Stock Chart
From Dec 2023 to Dec 2024